Clinical Trials in Seoul, Kangnamgu
2 recruiting
Showing 1–2 of 2 trials
Recruiting
Phase 2
Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)
Lung Cancer
Samsung Medical Center43 enrolled2 locationsNCT04591002
Recruiting
Phase 2
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell Lymphoma
Won Seog Kim37 enrolled1 locationNCT04763616